Prostate cancer news, treatments, therapies, and side effects from world-class doctors and clinicians. Malecare starts with truth from state-of-the-art real-world experience. Make sure your prostate cancer doesn’t kill you before something else does.
It’s Advanced Prostate Cancer that Kills Us. But not me, yet.
Newly Diagnosed With Prostate Cancer? Here’s how to stay alive.
Prostate Cancer Hurts LGBTQ+ People Differently. That’s truth.
I’ve Got a Huge Prostate. Prostatitis and BPH may hurt you more than Prostate Cancer.
Side effects suck. My doctor didn’t tell me I’d have ED , hot flashes, cold hours, and fatigue.
Prostate Cancer Kills Black Men at 2.4 times the rate as White Men. Read our stories.
Sometimes it’s easier to watch a prostate cancer video.
Stay informed about prostate cancer at Cancer Academy. Where patients get their superpowers. Making your doctor visits productive and tailored to your needs. Watch hundreds of one to three minute patient focused explainer videos.
Learn about prostate cancer with a free subscription to Malecare’s massive prostate cancer YouTube channel.
Ask how to end prostate cancer disparties.
Why does Prostate Cancer kill Black men at higher rates than White men? How do systemic racism, genetics, or environmental factors influence prostate cancer outcomes? Ask at: The Black Prostate Cancer Alliance
Why do other patient organizations marginalize transgender women with prostate cancer? Why do Gay and Bisexual men have worse prostate cancer quality of life than heterosexual men? Ask at: The National LGBT Cancer Project.
Improve prostate cancer research public policy.
Help pass the PathFinder Clinical Trial ACT
Increase Access to Prostate Cancer Clinical Trials
The PATHFINDER ACT advocates for a novel tax-based incentive to increase clinical trial participation by offering a $1,000 annual tax deduction to participants who complete a trial or are removed for health reasons. Rooted in behavioral economics, the proposal argues that financial incentives effectively reduce participation barriers, as demonstrated by existing research on stipends and reimbursements improving trial accrual rates. Broader economic and social benefits include enhancing trial diversity, reducing financial barriers, and improving the generalizability of research findings.